Guideline | Organization | Published |
HLA-B*15:02 and HLA-A*31:01 genetic testing to reduce the risk of carbamazepine-induced hypersensitivity reactions | Canadian Pharmacogenomics Network for Drug Safety Clinical Recommendation Group | 2014 |
CYP2C9 and HLA-B genotypes and phenytoin dosing | Clinical Pharmacogenetics Implementation Consortium | 2014 |
Cytochrome P450 2D6 genotype and codeine therapy - 2014 update | Clinical Pharmacogenetics Implementation Consortium | 2014 |
HLA-B Genotype and Abacavir Dosing - 2014 update | Clinical Pharmacogenetics Implementation Consortium | 2014 |
IFNL3 (IL28B) genotype and PEG interferon-α-based regimens | Clinical Pharmacogenetics Implementation Consortium | 2014 |
Incorporation of pharmacogenomics into routine clinical practice: the Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline development process | Clinical Pharmacogenetics Implementation Consortium | 2014 |
Ivacaftor therapy in the context of CFTR genotype | Clinical Pharmacogenetics Implementation Consortium | 2014 |
Rasburicase therapy in the context of G6PD deficiency genotype | Clinical Pharmacogenetics Implementation Consortium | 2014 |
SLCO1B1 and simvastatin-induced myopathy - 2014 update | Clinical Pharmacogenetics Implementation Consortium | 2014 |
Testing and clinical management issues associated with HLA and non-HLA antibodies in transplantation | Australian expert panel | 2013 |
CYP2D6 genotyping for safe and efficacious codeine therapy | Canadian Pharmacogenomics Network for Drug Safety Clinical Recommendation Group | 2013 |
CYP2C19 genotype and clopidogrel therapy - 2013 update | Clinical Pharmacogenetics Implementation Consortium | 2013 |
CYP2D6 and CYP2C19 genotypes and dosing of tricyclic antidepressants | Clinical Pharmacogenetics Implementation Consortium | 2013 |
Dihydropyrimidine dehydrogenase genotype and fluoropyrimidine dosing | Clinical Pharmacogenetics Implementation Consortium | 2013 |
HLA-B genotype and carbamazepine dosing | Clinical Pharmacogenetics Implementation Consortium | 2013 |
Human leukocyte antigen-B genotype and allopurinol dosing | Clinical Pharmacogenetics Implementation Consortium | 2013 |
Thiopurine methyltransferase genotype and thiopurine dosing - 2013 update | Clinical Pharmacogenetics Implementation Consortium | 2013 |
SLCO1B1 and simvastatin-induced myopathy | Clinical Pharmacogenetics Implementation Consortium | 2012 |
Testing for cytochrome P450 polymorphisms in adults with nonpsychotic depression treated with selective serotonin reuptake inhibitors | Evaluation of Genomic Applications in Practice and Prevention | 2007 |
No hay comentarios:
Publicar un comentario